Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date12 Mar 2024 |
安慰剂对照评价拈痛祛风颗粒治疗急性痛风性关节炎(风湿郁热证)的安全性和有效性的随机双盲多中心临床试验
[Translation] A placebo-controlled, double-blind, multicenter clinical trial evaluating the safety and efficacy of Niantong Qufeng Granules in the treatment of acute gouty arthritis (rheumatic heat syndrome)
进一步评价拈痛祛风颗粒治疗急性痛风性关节炎(风湿郁热证)的有效性和安全性。
[Translation] To further evaluate the efficacy and safety of Niantong Qufeng Granules in the treatment of acute gouty arthritis (rheumatic heat syndrome).
100 Clinical Results associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
100 Deals associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Chengdu Kangrui Pharmaceutical Co., Ltd.